Marshall D Snavely

Title: The Innovations of Marshall D. Snavely

Introduction

Marshall D. Snavely is a notable inventor based in Redmond, WA, who has made significant contributions to the field of biotechnology. He holds two patents that focus on innovative methods for inhibiting specific receptors involved in neovascular disorders. His work is particularly relevant in the context of cancer treatment and ocular disorders.

Latest Patents

Snavely's latest patents include compositions and methods for inhibiting PDGFRbeta and VEGF-A. These patents disclose antagonists of the PDGF receptor beta (PDGFRbeta) and VEGF-A, which include neutralizing anti-PDGFRbeta and anti-VEGF-A antibodies. The patents also describe bispecific antibodies capable of binding and neutralizing both PDGFRbeta and VEGF-A. Furthermore, the methods outlined in these patents provide approaches for treating neovascular disorders, such as cancer or neovascular ocular disorders, using PDGFRbeta and/or VEGF-A antagonists.

Career Highlights

Marshall D. Snavely is currently associated with Zymogenetics, Inc., where he continues to advance his research and development efforts. His work has been instrumental in creating therapeutic solutions that address critical health challenges.

Collaborations

Snavely has collaborated with notable colleagues, including Pallavur V. Sivakumar and Debra G. Gilbertson, contributing to a dynamic research environment that fosters innovation.

Conclusion

Marshall D. Snavely's contributions to biotechnology through his patents and collaborations highlight his role as a significant inventor in the field. His work continues to pave the way for advancements in treating neovascular disorders.